David J Webb

[vc_row][vc_column width=”1/4″]
[/vc_column][vc_column width=”3/4″]

Professor David J Webb, MD, MB BS MD DSc FRCP FRSE FAHA FESC FMedSci FFPM (Hon) FBPhS (Hon), United Kingdom

H-index: 109

[/vc_column][/vc_row]

[vc_row][vc_column]
[wm_tabs active=”1″ ]

[wm_item title=”Nomination Letter”]

On behalf of the British Pharmacological Society (BPS) we are delighted to nominate Professor David Webb CBE for the 2021 EACPT Lifetime Achievement Award in Clinical Pharmacology. Prof Webb has made a significant contribution to the discipline in terms of advancement of scientific knowledge and education. He has continued to demonstrate his dedication to the need for clinical pharmacology expertise in national and international healthcare.

Research and clinical career
Prof Webb has been a clinically active consultant physician, clinician scientist and clinical pharmacologist, running a European Society for Hypertension (ESH)-accredited Hypertension Excellence Centre in Edinburgh. His main clinical and research interests are in hypertension and cardiovascular risk management, but also include lipid disorders, type 2 diabetes, chronic kidney disease and clinical toxicology.
Prof Webb established the University of Edinburgh’s Clinical Research Centre in 1990 and Centre for Cardiovascular Science in 1998. He has made other contributions to the development of safe and effective medicines, as a non-executive director and Deputy Chair of the Medicines and Healthcare products Regulatory Agency and as Chair of the Scientific Advisory Committee for the National Institute of Biological Standards and Control (NIBSC, playing a leading national and international role in assuring the quality of biological medicines and diagnostics, including for COVID-19).
Supported mainly by the British Heart Foundation (BHF), Medical Research Council and Wellcome Trust, Prof Webb’s research focuses on the pathophysiology of hypertension and renal disease, particularly arterial structure and function, with work that has guided subsequent understanding of arterial stiffness, and the therapeutic potential of phosphodiesterase 5 inhibitors and endothelin receptor antagonists. He has published >500 peer-reviewed papers, and 5 books, on clinical pharmacology and cardiovascular disease. His work has received >45,000 citations (current h-index 109).
Prof Webb is a principal investigator in Edinburgh’s BHF Centre of Research Excellence (CoRE) and run its Hypertension and Renal Theme (HART), having won a competitive Wellcome Trust Cardiovascular Research Initiative (£7M (€7.9M) grant; 1998-2001) with which he established Edinburgh’s Centre for Cardiovascular Science in 2002 (since supported by a series of large BHF CoRE Awards). He was also a member of the core group responsible for raising funds to move research to the new Queen’s Medical Research Institute at Little France: £5M (€5.65M) BHF; £22.4M (€25.3M) Wellcome Trust; £27M (€30.5M) UoE). Previously, he ran Edinburgh’s University Department of Medicine (1997-2001) and have been President of the Scottish Society of Physicians (2010-11).

Education
Prof Webb teaches and trains undergraduate medical, pharmacy and Masters’ students, along with postgraduate scientists and physicians (lead/primary supervisor for >30 PhD and 14 MD degrees) and has done successfully for over five decades. He led two Translational Medicine & Therapeutics (TMT) PhD programmes for clinicians: the Scottish TMT initiative (STMTI; Wellcome Trust) and Scottish Clinical Pharmacology and Pathology Programme (SCP3; MRC). These were integral components of a UK-wide strategy to increase research power in clinical pharmacology and translational science. Many of his trainees have gone on to successful careers in medicine, academia and the pharmaceutical industry, including Profs David Newby, Duke of Edinburgh BHF Chair of Cardiology, Edinburgh; Michael Eddleston, Chair of Clinical Toxicology, Edinburgh; Bill Haynes, Vice President, Novo Nordisk Research Centre, Oxford; Brian Walker, Pro Vice Chancellor for Research & Chair of Medicine, Newcastle; and Ian Wilkinson, Director of Clinical Trials Unit, & Chair of Therapeutics, Cambridge.
Prof Webb co-wrote with Prof Simon Maxwell, a Commentary on the risks to UK clinical pharmacology (Lancet 2006;367:799), aimed at improving the NHS delivery of safer and better targeted medicines by medical graduates. This led, through a review chaired by Prof Sir Robert Lechler (Medical Schools Council Safe Prescribing Working Group: see Aronson J. Br J Clin Pharmacol 2010;69:111-7), to a revision of the GMC’s advice on undergraduate medical prescribing skills, and the delivery by BPS (with the UK Medical Schools Council) of the Award winning Prescribing Safety Assessment examination, now taken by all 8000+ UK medical students and overseas medical graduates entering the UK, which must be passed to enter FY2 training (Lancet 2019;394:283-5). In addition, the Lechler review led to the creation of UK translational medicine training programmes (SCP3 from MRC; STMTI from WT), with awards for both of which Prof Webb was a leader in Scotland.

National impact
Prof Webb is a non-executive director of the Medicines and Healthcare products Regulatory Agency (MHRA) and chairs the Scientific Advisory Committee at National Institute for Biological Standards and Control (NIBSC). He has previously been Chair of the Scottish Medicines Consortium, President of the Scottish Society of Physicians, and worked on reports from the Academy of Medical Sciences on Safer Medicines, Regulation and Governance of Medical Research and Evidence. Prof Webb has acted as advisor to Lord O’Shaughnessy on Brexit and medicines regulation, on behalf of MHRA.
Prof Webb has been awarded the BPS’s SKB Silver Medal for research in 1994, and Lilly Prize and Gold Medal for contributions to clinical pharmacology in 2003. Prof Webb’s contribution over the years as a BPS member is considerable, having led or supported numerous committees including: Clinical Section, Clinical Committee, Meetings Committee (where he was Vice-President for Meetings) and former Chair of the PSA Executive. In addition, Prof Webb has played a lead role in raising the profile of clinical pharmacology and therapeutics through publication (co-authoring a 2006 Lancet paper: Clinical Pharmacology – too young to die), supporting the Society’s campaign to demonstrate the value of clinical pharmacology in the NHS, leading our delivery of the Prescribing Safety Assessment in the UK, and regularly contributing to press articles on health and medicines.
Prof Webb was awarded Commander of the British Empire (CBE) in the Queen’s Birthday Honours 2020, for services to Clinical Pharmacology Research and Education.

International impact
David has been Honorary President of the European Society for Clinical Pharmacology & Therapeutics (EACPT) and a member of the Executive Committee of the International Union of Basic and Clinical Pharmacology (IUPHAR). He will be President of the World Congress of Pharmacology in 2022.
We highly commend him to the EACPT for this prestigious award.

Signed
Professor Sir Munir Pirmohamed, MB ChB (Hons), PhD, FRCP, FRCP(E), FFPM, FRSB, FBPhS, FMedSci
President, British Pharmacological Society

Rachel Lambert-Forsyth CBiol FRSB
Chief Executive, British Pharmacological Society
Managing Director, BPS Assessment Ltd

view original nomination letter

[/wm_item]

[wm_item title=”Curriculum Vitae”]

Personal Details

Prof. David J Webb, M.D.

download extended descriptive CV

ORCID ID: 0000-0003-0755-1756
Date of birth: 1st September, 1953

Work Address: Room E3.22, Pharmacology, Toxicology & Therapeutics
BHF Centre of Research Excellence (CoRE)
University of Edinburgh Queen’s Medical Research Institute
47 Little France Crescent Edinburgh EH16 4TJ Scotland, UK

Education:
1964 – 1971 Dulwich College (Kent Scholarship)
1972 – 1977 The Royal London Hospital Medical School (University of London)
University Degrees:
1977 MB BS University of London
1990 MD University of London
2000 DSc University of Edinburgh

Summary CV:
Education and training: Born in Greenwich and educated at Dulwich College and the Royal London Hospital,
I trained in general internal medicine, cardiology and clinical pharmacology & therapeutics, and held clinical
and research posts in London and Scotland, before appointment to the University of Edinburgh (UoE)’s
Christison Chair of Therapeutics & Clinical Pharmacology in 1995.
Clinical: In my career, I have been a clinically active consultant physician, clinician scientist and clinical
pharmacologist, running a European Society for Hypertension (ESH)-accredited Hypertension Excellence
Centre in Edinburgh. My main clinical and research interests are in hypertension and cardiovascular risk
management, but also include lipid disorders, type 2 diabetes, chronic kidney disease and clinical toxicology.
Research leadership (UoE): Supported mainly by the British Heart Foundation (BHF), Medical Research
Council and Wellcome Trust, my research focuses on the pathophysiology of hypertension and renal disease,
particularly arterial structure and function, with work that has guided subsequent understanding of arterial
stiffness, and the therapeutic potential of phosphodiesterase 5 inhibitors and endothelin receptor
antagonists. I have published >500 peer-reviewed papers, and 5 books, on clinical pharmacology and
cardiovascular disease. My work has received >45,000 citations (current h-index 109).
I am a principal investigator in Edinburgh’s BHF Centre of Research Excellence (CoRE) and run its
Hypertension and Renal Theme (HART), having won a competitive Wellcome Trust Cardiovascular Research
Initiative (£7M (€7.9M) grant; 1998-2001) with which I established Edinburgh’s Centre for Cardiovascular
Science in 2002 (since supported by a series of large BHF CoRE Awards). I was also a member of the core
group responsible for raising funds to move research to the new Queen’s Medical Research Institute at Little
France: £5M (€5.65M) BHF; £22.4M (€25.3M) Wellcome Trust; £27M (€30.5M) UoE). Previously, I ran
Edinburgh’s University Department of Medicine (1997-2001) and have been President of the Scottish Society
of Physicians (2010-11).
Teaching and training (UoE): I teach and train undergraduate medical, pharmacy and Masters’ students,
along with postgraduate scientists and physicians (lead/primary supervisor for >30 PhD and 14 MD degrees).
I have led two Translational Medicine & Therapeutics (TMT) PhD programmes for clinicians: the Scottish TMT
initiative (STMTI; Wellcome Trust) and Scottish Clinical Pharmacology and Pathology Programme (SCP3;
MRC). These were integral components of a UK-wide strategy to increase research power in clinical
pharmacology and translational science. Many of my trainees have gone on to successful careers in medicine,
academia and the pharmaceutical industry, including Profs David Newby, Duke of Edinburgh BHF Chair of
Cardiology, Edinburgh; Michael Eddleston, Chair of Clinical Toxicology, Edinburgh; Bill Haynes, Vice President,
Novo Nordisk Research Centre, Oxford; Brian Walker, Pro Vice Chancellor for Research & Chair of Medicine,
Newcastle; and Ian Wilkinson, Director of Clinical Trials Unit, & Chair of Therapeutics, Cambridge.
Leadership of the British Pharmacological Society (BPS): My main academic discipline is pharmacology, with
my interests spanning pharmacology, clinical pharmacology and therapeutics (CPT), as well as the costeffectiveness
of medicines and the ethics of research. As a UK-based pharmacologist, my national learned
society is the BPS. I am Past President, having previously held a number of posts, including Vice President
(Clinical), Vice President (Meetings), President Elect and President. BPS awarded me the SKB Silver Medal for
research (1994), and the Lilly Prize and Gold Medal for longstanding contributions to CPT (2003).
Support for clinical pharmacology: With an Edinburgh colleague, Prof Simon Maxwell, I co-wrote a
Commentary on the risks to UK clinical pharmacology (Lancet 2006;367:799), aimed at improving the NHS
delivery of safer and better targeted medicines by medical graduates. This led, through a review chaired by
Prof Sir Robert Lechler (Medical Schools Council Safe Prescribing Working Group: see Aronson J. Br J Clin
Pharmacol 2010;69:111-7), to a revision of the GMC’s advice on undergraduate medical prescribing skills,
and the delivery by BPS (with the UK Medical Schools Council) of a Prescribing Safety Assessment
examination, now taken by all 8000+ UK medical students and overseas medical graduates entering the UK,
which must be passed to enter FY2 training (Lancet 2019;394:283-5). In addition, the Lechler review led to
the creation of UK translational medicine training programmes (SCP3 from MRC; STMTI from WT), with
awards for both of which I was a leader in Scotland.
Leadership in international pharmacological associations: I am a past Executive Committee member of
EACPT and hosted its biennial international meeting in Edinburgh in 2009. I am a current Executive
Committee member of the International Union of Basic and Clinical Pharmacology (IUPHAR), the global
overarching organisation for pharmacology, having been its Clinical President for 2 years (2017-18). I am also
future President of IUPHAR’s World Congress of Basic & Clinical Pharmacology, to be held in Glasgow.
Leadership at Medicines and Healthcare products Regulatory Agency (MHRA): I have been Deputy Chair of
MHRA Unitary Board since 2018, and Non-Executive Director since 2013. I have chaired the newly reestablished
NIBSC Scientific Advisory Committee since 2014, helping to reorganize and integrate its science,
ensure regular external reviews of its divisions, and renew its quinquennial funding from DHSC/NIHR to
support research. I also take a major interest in the Clinical Practice Research Datalink (CPRD), supporting its
wider uptake and the broader use of real-world data.
Leadership within the NHS in HTA: Working in Scotland for 30 years, a proportion of my non-academic time
has been used to support Scottish NHS/Government initiatives. I helped establish the Scottish Medicines
Consortium (SMC), Scotland’s equivalent of NICE single technology assessment. This was a multi-disciplinary
approach to health technology assessment (HTA) involving the NHS, academia, and the pharmaceutical
industry. I chaired SMC’s New Drugs Committee (2001-2004) and SMC Board (2004-2008) with stakeholders
including physicians, health economists and health service managers, as well as representatives from
industry, patient and public bodies and Scottish Government. We worked closely with leaders at NICE,
including Sir Andrew Dillon (CEO) and Sir Mike Rawlins (Chair), to support the role of HTA within the UK NHS,
and to persuade the public and pharmaceutical industry of its value.
Leadership within the Royal Colleges: I worked with the Royal College of Physicians (London) as Chair of the
Clinical Pharmacology Committee (1998-2000), and was involved in two working groups, leading to influential
reports on “Clinical Pharmacology & Therapeutics in a Changing World” and “Costly Medicines”. I was Vice-
President of the Royal College of Physicians (Edinburgh: 2006-09) and remain Clinical Training Programme
Director for Clinical Pharmacology & Therapeutics in Scotland (twice: 2007-10 and since 2014).
Working with industry: I have worked with industry on translational studies helping to direct the
development of renin inhibitors, angiotensin receptor blockers, phosphodiesterase inhibitors and endothelin
receptor antagonists (mainly with GSK, Pfizer and Roche, as well as Actelion and Alnylam). In 2011 I helped
to establish Edinburgh’s Wellcome Trust Clinical Research Facility as the first academic MHRA-accredited
first-in-human centre in the UK.
I am a founder member of the UK Clinical Pharmacology Skills Alliance (CPSA), which is a formal ongoing
collaboration between BPS, the Association of the British Pharmaceutical Industry (ABPI) and the Faculty of
Pharmaceutical Medicine (FPM). I have engaged with BPS, MRC, ABPI and FPM over many years, and spoken
at the ABPI’s annual meetings, to gain recognition of the need to promote careers in clinical pharmacology.
Communication, media and public engagement: I speak widely at international research meetings (Europe,
US & Asia), and have organised UK, European and World Congresses on hypertension, pharmacology and
endothelin biology. I have given evidence at Scottish and Westminster Parliaments on drug safety,
prescribing skills and value for money in new medicines. I work regularly with the UK Science Media Centre.
I also enjoy engaging with the public on topics that matter to them (often related to medicines) and in
debates on priorities and values. In the recent past, I have been involved in debates and discussions at the
Cheltenham Science Festival and Edinburgh Science Festival discussing equity and efficiency in managing NHS
budgets. I also advised on, and narrated, an award-winning television drama documentary on the TGN-1412
disaster at Northwick Park (“When a drug trial goes wrong: emergency at the hospital”).

MAJOR ROLES
Academic: Current [University of Edinburgh unless otherwise stated]
2015 Chair, Hypertension and Renal Theme (HART), Centre for Cardiovascular Science
2004 Research Strategy Group, BHF Centre of Research Excellence (CoRE)
1995 Christison Professor of Therapeutics and Clinical Pharmacology
1990 Director, University of Edinburgh’s Clinical Research Centre
Academic: Previous
2016-2019 Clinical Trials Committee, British Heart Foundation (BHF)
2010-2014 Pharmacology Lead, MRC Clinical Pharmacology & Pathology Programme
2010-2011 President, Scottish Society of Physicians
2008-2015 Director, Wellcome Trust Translational Medicine & Therapeutics Initiative
2008-2010 Faculty, National Institute for Health Research
2006-2015 Collaborative Research Steering Group, British Hypertension Society
2002-2004 College of Medicine and Veterinary Medicine Research Committee
2001-2004 Strategic Co-ordinating Group: Transfer to Little France
2000-2004 Head, Centre for Cardiovascular Science
1999-2001 Convenor, Cardiovascular Interdisciplinary Group
1998-2000 Little France Research Institute Project Board
1998-2001 Leader, Wellcome Trust Cardiovascular Research Initiative
1997-2001 Head, Department of Medicine, University of Edurgh
1990-1995 Senior Lecturer in Medicine
1985-1985 Lecturer, Clinical Pharmacology, St George’s Medical School, University of London
1982-1985 MRC Clinician Scientist, MRC Blood Pressure Unit, University of Glasgow

Educational
2016- Director, UK CPT Mentoring Scheme, IUPHAR
2014-2019 Chair, Executive Board, UK Prescribing Safety Assessment (BPS)
1998-2015 Director, Education Programme, Wellcome Trust Clinical Research Facility
1998-2001 Management Board, Trans-Faculty Wellcome Trust 4-Year PhD Programme
1996-1998 Medical Education Committee’s Curriculum Review: VISION 2000
National Health Service
2014- Training Programme Director, SE Scotland, Clinical Pharmacology & Therapeutics
2007- Director, Edinburgh ESH Centre of Excellence in Hypertension
1990- Honorary Consultant Physician, Lothian University Hospitals NHS Trust
2003-2006 Chair, CVD/Stroke Research Portfolio Steering Group, Scot. Executive Health Dept
2001-2010 National Specialty Adviser Clinical Pharmacology, Scot Executive Health Dept
1998-2001 Chair, Committee on Clinical Pharmacology, Royal College of Physicians, London
1997-2001 Clinical Pharmacologist, Multi-centre Research Ethics Committee for Scotland
1993-2003 Lothian Research Ethics Committee, Faculty of Medicine Representative
1985-1989 Honorary Senior Registrar in Medicine, St. George’s Hospital, London
1982-1985 Honorary Registrar in Medicine, Western Infirmary, Glasgow
1980-1982 Registrar: Medical rotational scheme: Royal London Hospital
1977-1980 Junior medical posts: The Royal London Hospital scheme

Regulatory
2021- Member, Patient Safety and Engagement Committee, MHRA
2018- Deputy Chair, MHRA Unitary Board
2014- Chair, Scientific Advisory Committee, NIBSC
2014-2016 Member, Audit & Risk Assessment Committee, MHRA
2013- Non-Executive Director, MHRA Board (reappointed 2016)
2004-2008 Chair, Scottish Medicines Consortium
2002-2012 Chair, Advisory Board, Centre for Adverse Drug Reactions Scotland (CARDS)
2001-2004 Chair, Scottish Medicines Consortium New Drugs Committee
2001-2004 Vice Chair, Scottish Medicines Consortium
1996-2001 Chair, Lothian Area Drug & Therapeutics Committee

Learned Societies
2022- President, 19th World Congress of Basic & Clinical Pharmacology, IUPHAR
2017- Co-founder, Clinical Pharmacology Skills Alliance (CPSA; academic/industry)
2014- Executive Committee member, IUPHAR
2017-2018 Chair, Clinical Division, IUPHAR
2016-2017 President, British Pharmacological Society
2014-2015 President Elect, British Pharmacological Society
2011-2013 Vice President (Meetings), British Pharmacological Society
2006-2009 President, European Association for Clinical Pharmacology & Therapeutics
2006-2009 Vice President, Royal College of Physicians, Edinburgh

External Grant Review
2016-2019 BHF Clinical Trials Committee
2008-2011 MRC Efficacy and Mechanism Evaluation (EME) Programme, NIHR
2004-2007 French National Institute of Health, Département de l’Evaluation Scientifique, Inserm
evaluation expert adviser for projects and site visits
2004-2008 BHF Project Grants Committee (Chair)
2001-2005 Health Research Board (HRB) for Ireland Programme Grants Committee
1997-2000 The Wellcome Trust Physiology & Pharmacology Panel
1996-1998 MRC, Physiological Medicine Grants Committee

Working Parties/Reports
2017 Methods of evaluating evidence; Academy of Medical Sciences (AMS)
2015 Ensuring UK leadership in experimental medicine; ABPI/BPS
2013 Chair, Task and Finish Group on Scottish Medicines Consortium; Scot Govt
2011 The regulation and governance of medical research; AMS
2010 Advisory Board, Department of Trade & Industry Innovation Pass
2009 Office of Life Sciences Blueprint, Clinical Pharmacology Task & Finish Group
2008 Scottish Management of Antimicrobial Resistance Action Plan; Scottish Government
2008 Complementary and Alternative Medicines; AMS
2008 Witness, Physicians & Pharma Industry Working Party, Royal College of Physicians
2007 Short Life Working Group on Safe Prescribing: GMC/Medical Schools Council/et al.
2007 Adviser, Board of Science Working Party on Evidence-Based Prescribing; BMA
2007 Chair, Working Party Meeting on Safe Prescribing; Joint BPS/European Association for Clinical
Pharmacology & Therapeutics
2007 Short Life Working Group on Consistent Advice; Scottish Medicines Consortium, Scottish
Intercollegiate Guidelines Network & Quality Improvement Scotland
2006 Co-Chair, Towards Better Safety Assessment of Medicinal Products; AMS
2000 Prescribing of Costly Medicines; Royal College of Physicians, London
2000 Consensus on Misconduct in Biomed. Research; Royal College of Physicians (Edin)
2000 Management of Hypertension: Scottish Intercollegiate Guidelines Network
1999 Clinical Pharmacology in a Changing World; Royal College of Physicians, London

Fellowships
2017 Academia Europaea
2014 British Hypertension Society (first elected cohort; FBHS)
2004 British Pharmacological Society (FBPhS)
2004 Royal Society of Edinburgh (FRSE)
2001 European Society of Cardiology (FESC)
1999 Academy of the Medical Sciences (first elected cohort; FMedSci)
1996 American Heart Association (International Fellowship; FAHA)
1994 Royal College of Physicians, London (FRCP Lond)
1993 Faculty of Pharmaceutical Medicine (FPM) by distinction
1992 Royal College of Physicians, Edinburgh (FRCP Edin)
Other Awards & Distinctions
2020 Awarded CBE (Commander of the British Empire) in the Queen’s Birthday Honours
2020 Council Member, Academy of Medical Sciences
2019 Chair, Trustees of the Edinburgh High Blood Pressure Fund
2018 Honorary Fellowship, British Pharmacological Society
2017 Fourth Tomoh Masaki Award, ET-15 (previously to Yanagisawa, Goto, Clozel)
2017 BHF Advisory Council
2017 Biennial Scientific Award, European Association for Clinical Pharmacology
2016 Honorary Fellowship, Faculty of Pharmaceutical Medicine
2016 Finalist, BMA Awards Education Team of the Year (Prescribing Safety Assessment)
2016 Finalist, BMA Awards Research Team of the Year (PATHWAY-2 trial)
2014 Nominated as President, 19th IUPHAR World Congress of Pharmacology (2022)
2003 Lilly Biennial Prize & Gold Medal for distinction in Clinical Pharmacology, BPS
1999 RD Wright (Howard Florey) Lecturer, High Blood Pressure Council of Australia
1998 Diploma Clin Pharm Honoris Causa, Worshipful Society of Apothecaries, London
1998 Research Leave Fellowship, Wellcome Trust (1998-2001)
1994 SKB Biennial Prize & Silver Medal for distinction in research, BPS
1994 Austin Doyle Prize Lecture, International Society of Hypertension

Large Grants
– Infrastructural grants
2013 BHF. Research Excellence Award (RE/13/3/30183). £3,000,000 (€3,389,289). Professors M Bradley, KAA
Fox, T Freeman, N Hastie, JJ Mullins (PI), DE Newby, B Peault, JR Seckl, BR Walker, Prof DJ Webb;
external – Professors A Cowley, J Girkin, C MacRae.
2008 BHF. Research Excellence Award (RE/08/001/23904). £7,600,000 (€8,586,200). Professor KAA Fox (PI),
A Harmar, JJ Mullins, DE Newby, J Savill, JR Seckl, BR Walker, Prof DJ Webb, I Wilmut; external –
Professors J Girkin, C MacRae.
2004 MRC. Health Informatics Consortium. £1,998,412 (€2,257,732). Profs MP Atkinson, Paul Boyle, Sir A
Cuscheiri, P Davey, C Goble, A Grant, T MacDonald, R Marshall, A Morris, J Norrie, N Pitts, IW Ricketts,
F Sullivan (PI). Prof DJ Webb as named collaborator on behalf of the Scottish Medicines Consortium.
2003 BHF Second Cardiovascular Initiative. Infrastructural Grant. Proposal for a BHF Imaging Centre in
Edinburgh. £2,243,773 (€2,534,932). Prof KAA Fox (PI), Prof DJ Webb, Prof JJ Mullins, Prof JR Seckl,
Prof BR Walker, Prof N McDicken, Dr I Marshall & Dr DE Newby.
2002 Science Research Investment Fund and Scottish Higher Education Funding Council (SRIF/SHEFC).
Establishment of a Research Institute for Medical Cell Biology at the New Royal Infirmary of
Edinburgh. £22,400,000 (€25,306,694). Building over 3 years. Prof C Haslett (PI), Prof H Critchley, Prof
KAA Fox, Prof A McNeilly, Prof R Miller, Prof JJ Mullins, Prof J Savill, Prof JR Seckl, and Prof DJ Webb.
1999 BHF Cardiovascular Initiative. Infrastructural Grant. Facility for Integrative Cardiovascular Research.
July 1999. £5,099,457 (€5,761,179). Prof KAA Fox, Prof JR Seckl, Prof DJ Webb (PI).
1998 The Wellcome Trust. Cardiovascular Research Initiative. £7,000,000 (€7,908,342). for 7 years.
Professor KAA Fox, Professor C Haslett, Dr JJ Mullins, Professor JR Seckl, Prof DJ Webb (PI).
1997 The Wellcome Trust. “Clinical Research Facilities Initiative”. £4,045,493 (€4,570,449). Prof DJ Webb
(Director: Cardiovascular Programme & Research Training Programme) and others. Research Director
and Application Coordinator: Prof PC Butler.
– Research grants
2016 BHF. Clinical Study (CS/16/1/31878). Clinical study of UMOD NKCC2 interaction on salt-sensitivity in
hypertension. £653,756 (€738,589). June 2016 for 3.5yrs. Padmanabhan S (PI), Macdonald T, Webb
DJ.
2014 BHF. Clinical Study (CS/14/1/30659). Treatment In the Morning versus Evening (TIME) Study. Brown
M, Ford I, McDonald T (PI), Mackenzie I, Webb DJ, Williams B. £1,059,948 (€1,197,490).
2012 BHF Special Project (SP/12/8/29620). A randomized open-label branded endpoint trial to compare the
effects of spironolactone to chlortalidone on left ventricular mass and arterial stiffness in stage 3
chronic kidney disease (SPIRO-CKD). £964,216 (€1,089,336). Dr C Ferro, Dr JN Townsend (PI), Prof DJ
Webb, Dr D Wheeler, Dr IB Wilkinson.
2008 BHF. Programme Grant (SP/08/002). A Programme for Prevention And Treatment of Resistant
Hypertension With Algorithm based TherapY (PATHWAY). Supplement of £691,351: £2,585,802
(€2,921,344). Professors M Brown (PI), M Caulfield, I Ford, T Macdonald, G Macgregor, G McInnes, N
Poulter, P Sever, D Webb and B Williams.
– Research training grants
2013 BHF. Intermediate Clinical Research Fellowship (FS/13/30/29994) for Dr Neeraj Dhaun. Macrophage
regulation of the pro-hypertensive and pro-inflammatory effects of endothelin-1. £757,149
(€855,399). Sponsor: Prof DJ Webb.
2010 MRC Clinical Pharmacology and Pathology Fellowship Programme. (G1000419). Scottish Clinical
Pharmacology and Pathology Programme (SCP3). From September 2010 for 5 years. £1,849,964
(€2,090,021). Profs Iain McInnes (Programme Lead); Prof David Webb (Clinical Pharmacology Lead);
Prof David Harrison (Pathology Lead).
2009 BHF. Four-Year PhD Programme. £3,000,000 (€3,389,289). D Webb as co-principal supervisor (14
total). Coordinator: M Bailey.
2008 The Wellcome Trust. Edinburgh Clinical Academic Track (ECAT) Clinical PhD Training Programme.
£5,100,000 (€5,761,792). Prof J Iredale (Director) and Prof BR Walker (Deputy Director). Prof DJ
Webb (Programme supervisor, and Lead, Wellcome Trust CRF Education Programme) and others.
2008 Wellcome Trust/Wyeth. Scottish Translational Medicine and Therapeutics Initiative (STMTI) (WT
085664). £5,500,000 (€6,213,697). Prof DJ Webb (PI; Director) and Prof IB McInnes (Deputy Director),
and others.

download CV 

[/wm_item]
[wm_item title=”Publications”]

Publications
Original research papers: >350 Citations: >45,000 H-Index: 109
Review papers: >250 Authored books: 7 Book chapters: >40
Reports & monographs: >20

download selected list of publications

Selected Original Research Papers (from >350)
1. Anand A, Farrah TE, Miller-Hodges E, Shah ASV, Strachan FE, Carter E, Johnston NR, Webb DJ, Mills
NL, Dhaun N. Serial troponin measurements to monitor risk and response to endothelin A
antagonism in chronic kidney disease. Nephrol Dial Transplant 2021;36:375-7.
2. European Society of Hypertension COVID-19 Task Force. The Covid-19 pandemic compromised
routine care for hypertension: a survey conducted among Excellence Centers of the European Society
of Hypertension. J Hypertens 2021;39:190-5.
3. Crosse EI, Gordon-Keylock S, Rybtsov S, Binagui-Casas A, Felchle H, Nnadi NC, Kirschner K, Chandra
T, Tamagno S, Webb DJ, Rossi F, Anderson RA, Medvinsky A. Multi-layered spatial transcriptomics
identify secretory factors promoting human haematopoietic stem cell development. Cell Stem
Cell 2020;27:822-39
4. Farrah TE, Anand A, Gallacher PJ, Kimmitt R, Carter E, Dear JW, Mills NL, Webb DJ, Dhaun N.
Endothelin receptor antagonism improves lipid profiles and lowers PCSK9 (proprotein convertase
subtilisin/kexin type 9) in patients with chronic kidney disease. Hypertension 2019;74:323-30.
5. Heerspink HJL, Parving H-H, Andress DL, et al., on behalf of the SONAR Committees and
Investigators (Webb DJ, DMEC Member). Atrasentan and renal events in patients with type 2
diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Lancet 2019;393:1937-47.
6. Czopek A, Moorhouse R, Guyonnet L, Farrah T, Lenoir O, Owen E, van Bragt J, Costello HM,
Menolascina F, Baudrie V, Webb DJ, Kluth DC, Bailey MA, Tharaux PL, Dhaun N. A novel role for
myeloid endothelin-B receptors in hypertension. Eur Heart J 2019;40:768–84.
7. Culshaw GJ, Costello HM, Binnie D, Stewart KR, Czopek A, Dhaun N, Hadoke PWF, Webb DJ, Bailey
MA. Impaired pressure natriuresis and non-dipping blood pressure in rats with early type 1
diabetes mellitus. J Physiol 2019;597:767-80
8. Williams B, MacDonald TM, Morant SV, Webb DJ, et al. for the British Hypertension Society’s
PATHWAY Studies Group. Endocrine and haemodynamic changes in resistant hypertension, and
blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
Lancet Diabetes Endocrinol 2018;6:464-75.
9. Brown MJ, Williams B, Morant SV, Webb DJ, et al. for the British Hypertension Society’s PATHWAY
Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus
hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group,
double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 2016;4:136-47.
10. Williams B, MacDonald TM, Morant S, Webb DJ, et al. for the British Hypertension Society’s
PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine
the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind,
crossover trial. Lancet 2015;386:2059-68.
11. Bateman DN, Dear JW, Thanacoody HKR, Thomas SHL, Eddleston M, Sandilands EA, Coyle J, Copoper
JG, Rodriguez, A, Butcher I, Lewis SC, Vliegenthart ADB, Webb DJ, Gray A. Reduction of adverse
effects from intravenous acetylcysteine treatment for paracetamol poisoning: randomized
controlled trial. Lancet 2014;383:697-704.
12. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event
prediction: an individual participant meta-analysis of prospective observational data from 17,635
subjects. J Am Coll Cardiol 2014;63:636-646. [cited >1000 times]
13. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)
Research Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg
simvastatin daily in 12064 survivors of myocardial infarction: a double-blind randomised trial. Lancet
2010;376:1658-69
14. The ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl
J Med 2009;361:1953-62.
15. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. Blood
pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A
receptor antagonism in chronic kidney disease. Hypertension 2009;54:113-9.
16. Heaton A, Webb DJ, Maxwell SRJ. Undergraduate preparation for prescribing: the views of 2413 UK
medical students and recent graduates. Br J Clin Pharmacol 2008;66:128-34.
17. Gudmundsdóttir IJ, Lang NN, Boon NA, Ludlam CA, Webb DJ, Fox KA, Newby DE. Role of the
endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in
humans. J Am Coll Cardiol 2008;51:1749-56.
18. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension.
Hypertension 2006;48:622-7.
19. Goddard J, Eckhart C, Johnston NR, Cumming AD, Rankin AJ, Webb DJ. Endothelin A receptor
antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B
receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 2004;15:2601-10.
20. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ. Endothelin-A
receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients
with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.
Circulation 2004;109:1186-93.
21. Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ. Potentiation of bradykinininduced
tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll
Cardiol 2001;38:1402-8.
22. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the vasodilator
effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation
2001;104:177-81.
23. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on
augmentation index and central arterial pressure in humans. J Physiol (Lond) 2000;525:263-70. [cited
>1000 times]
24. Kyriakides ZS, Kremastinos DT, Kolettis TM, Tasouli A, Antoniadis A, Webb DJ. Acute local endothelinA
receptor antagonism prevents normal reduction of myocardial ischemia on repeated balloon
inflations during angioplasty. Circulation 2000;102:1937-43.
25. Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the
hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol
2000;36:25-31.
26. Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and
sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology
2000;118:565-72.
27. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KAA, Boon NA, Webb DJ. Endothelial dysfunction,
impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and
myocardial infarction. Circulation 1999;99:1411-5.
28. McEwan PE, Gray GA, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell
proliferation and intracoronary perivascular fibrosis in vivo. Circulation 1998;98:2765-73.
29. Newby DE, Flint LL, Fox KAA, Boon NA, Webb DJ. Reduced responsiveness to endothelin-1 in
peripheral resistance vessels of patients with syndrome X. J Am Coll Cardiol 1998;31:1585-90.
30. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, Webb DJ. The reproducibility
of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens
1998;16:2079-84. [cited >1000 times]
31. Walker BR, McConnachie A, Noon JP, Webb DJ, Watt GCM. Contribution of parental blood pressures
to association between low birth weight and adult high blood pressure: cross-sectional study. BMJ
1998;316:834-837.
32. Ferro CJ, Spratt JCS, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes
vasoconstriction of human resistance vessels in vivo. Circulation 1998;97:2323-30.
33. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-A
receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and
by endothelin-B receptor blockade. Circulation 1998;97:752-6.
34. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, Watt GCM. Impaired
microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood
pressure. J Clin Invest 1997;99:1873-9.
35. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJV. Vasodilator effects of endothelinconverting
enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients
treated with ACE inhibitors. Circulation 1996;94:2131-7.
36. Haynes WG, Ferro CJ, O’Kane KPJ, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor
blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation
1996;93:1860-70.
37. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JMC. Endothelial nitric oxide production and insulin
sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease.
Circulation 1996;93:1331-3.
38. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of
human resistance and capacitance vessels in vivo. Circulation 1995; 92:357-63.
39. Haynes WG, Hand MF, Johnstone HA, Padfield PL, Webb DJ. Direct and sympathetically mediated
venoconstriction in essential hypertension: enhanced responses to endothelin-1. J Clin Invest
1994;94:1359-64.
40. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular
tone. Lancet 1994;344:852-4.
41. Haynes WG, Noon JP, Walker BR, Webb DJ. L-NMMA increases blood pressure in man. Lancet
1993;342:931-2.
42. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal vascular responses to supine exercise
in hypertrophic cardiomyopathy. Circulation 1991;84:686-96.
43. Benjamin N, Cockcroft JR, Collier JG, Dollery CT, Ritter JM, Webb DJ. Local inhibition of converting
enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol (Lond)
1989;412:543-55.
44. Clarke JG, Benjamin N, Larkin SW, Webb DJ, Davies GJ, Maseri A. Endothelin is a potent long-lasting
vasoconstrictor in men. Am J Physiol 1989;257:H2033-5.
45. Hodsman GP, Isles CG, Murray GD, Usherwood TP, Webb DJ, Robertson JIS. Factors related to first
dose hypotensive effect of captopril: prediction and treatment. BMJ 1983;286:832-4.
46. Webb DJ, Cumming AMM, Leckie BJ, Lever AF, Morton JJ, Robertson JIS, Szelke M, Donovan B.
Reduction of blood pressure in man with H-142, a potent new renin inhibitor. Lancet 1983;ii:1486-7.

Selected Review Articles (from >250)
1. Guthrie G, Poulter N, Macdonald T, Ford I, Mackenzie I, Findlay E, Williams B, Brown M, Lang C,
Webb D. Commentary – Chronotherapy in hypertension: the devil is in the details. Eur Heart J.
2020;41:1606-7.
2. Farrah TE, Dhillon B, Keane PA, Webb DJ, Dhaun N, The eye, the kidney & cardiovascular disease:
old concepts, better tools, & new horizons Kidney Int 2020;98:323-42
3. Tzoumas N, Farrah TE, Dhaun N, Webb DJ. Established and emerging therapeutic uses of
phosphodiesterase type 5 inhibitors in cardiovascular disease. Br J Pharmacol 2020;177:5467-88.
4. Maxwell SRJ, Webb DJ. Improving medication safety: focus on prescribers and systems. Lancet
2019;394:283-5.
5. Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nature Rev Cardiol
2019;16:491-502.
6. Farrah TE, Webb DJ, Dhaun N. Retinal ‘fingerprints’ for precision cardiovascular risk profiling.
Nature Rev Cardiol 2019;16:379-81.
7. Maxwell SR, Cameron IT, Webb DJ. Prescribing safety: ensuring that new graduates are prepared.
Lancet 2015;385:579-81.
8. Webb DJ. Value-based medicine pricing: NICE work? Lancet 2011;377:1552-1553.
9. Dhaun N, Webb DJ. Endothelin-receptor antagonism: the future is bright. Lancet 2008;371:2061-2
10. Webb DJ, Walker A. Value based pricing of drugs in the UK. Lancet 2007;369:1415-6.
11. Carlson RV, van Ginneken NH, Pettigrew LM, Davies A, Boyd KM, Webb DJ. The three official
language versions of the Declaration of Helsinki: what’s lost in translation? J Med Ethics 2007;33:545-
12. Aronson JK, Henderson G, Webb DJ, Rawlins MD. A prescription for better prescribing. BMJ
2006;333:459-60.
13. Maxwell S, Webb DJ. Clinical pharmacology: too young to die? [Commentary] Lancet 2006;367:799-
800.
14. Dillon A, Hutton P, Webb D, Walker R, Catchpole P, Parkin D. Appraise be. Health Serv J
2005;115:suppl 6-7, 9-11.
15. Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of
endothelial function in humans. Arterioscl Thromb Vasc Biol 2005;25:2470-9.
16. Camidge R, Walker A, Oliver JJ, Nussey F, Maxwell S, Jodrell D, Webb DJ. Prognosis without treatment
as a modifier in health economic assessments. Br Med J 2005;330:1382-4.
17. Maxwell SRJ, Webb DJ. Cox-2 selective inhibitors: important lessons learned [Commentary]. Lancet
2005;365:449-51.
18. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ,
Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ. Endothelial function and
dysfunction. Part I: Methodological issues for assessment in the different vascular beds: A statement
by the Working Group on Endothelins and Endothelial Factors of the European Society of
Hypertension. J Hypertens 2005;23:7-17. [cited >800 times]
19. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia
G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ.
Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and
diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European
Society of Hypertension J Hypertens 2005;23:233-46. [cited >700 times]
20. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events.
Arterioscl Thromb Vasc Biol 2003;23:554-66. [cited >1000 times]
21. Thomson AJ, Grant IS, Webb DJ, Maxwell SRJ. Oxygen therapy in acute medical care: too much of a
good thing. Br Med J 2002;324:1406-7.
22. Affolter J, Webb DJ. Urotensin II: a new mediator in cardiopulmonary regulation? [Commentary].
Lancet 2001;358:774-5.
23. Wilkinson IB, Webb DJ, Cockcroft JR. Isolated systolic hypertension: a radical rethink [Editorial]. Br
Med J 2000;320:1685.
24. Newby DE, Webb DJ. The endothelin system in cardiovascular disease: discovery to drug
development in under a decade. Br Med J 1997;314:531-2.
25. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and
interpreting the responses to drugs and mediators. Hypertension 1995;25:918-23.
26. Webb DJ, Haynes WG. Endothelins come of age. Lancet 1993;342:1439-40.
27. Webb DJ, Haynes WG. European Community guidelines for clinical trials. Eur J Int Med 1992;3:5-8.
Selected books (from 5)
1. Vallance PJT & Webb DJ (editors). Vascular Endothelium in Human Physiology and Pathophysiology.
Harwood Academic Publishers, London, 1999, pp 285. ISBN: 90-5702-489-6.
2. Webb D & Vallance P (editors). The Endothelium in Hypertension. Springer-Verlag, Berlin 1997 pp
154. ISBN: 3-54062943-2.
3. Gray GA & Webb DJ (editors). The molecular biology and pharmacology of the endothelins.
Molecular Biology Intelligence Unit Monograph Series, RG Landes Co., Austin, Texas, USA, 1995, pp
173. ISBN: 3-540-59425-6.

Selected Reports and Monographs (from >20)
1. Samer C, Webb D, Mannaioni G, Watanabe H, Gook Shin J, Coleman J, Lucena MI, Doogue M,
Kshirsagar N, Ogunleye O, Hilmer S, Wei W. Considerations in the context of the COVID-19
pandemic. Report from the International Union for Basic and Clinical Pharmacology (IUPHAR)
Clinical Division. May 2020. https://iuphar.org/wp-content/uploads/2020/05/IUPHAR-Clinical-
Division-Considerations-in-the-Context-of-COVID-19-Pandemics.pdf
2. Al-Shahi Salman R, Dawson J, Drylie I, Forsyth P, Hendry A, Mackenzie I, McKinstry B, Padmanabhan
S, Touyz R, Webb D. Beating High Blood Pressure: Scotland’s Silent Killer. A Report by the Cross-
Party Group on Heart Disease and Stroke. pp. 1-17. January 2019. https://www.bhf.org.uk/-
/media/files/heart-voices/beating-high-blood-pressure-scotlands-silent-killer-report-final.pdf?la=en
3. Next Steps for Using Real World Evidence: Summary of a Report of a Forum Follow-Up Roundtable
from the Academy of Medical Sciences, January 2018. https://acmedsci.ac.uk/filedownload/
7021031
4. Sources of Evidence for Assessing the Safety, Efficacy and Effectiveness of Medicines (Chair: Sir
Michael Rutter), A report from the Academy of Medical Sciences, June 2017.
https://acmedsci.ac.uk/file-download/86466482
5. Real World Evidence. A report from the Academy of Medical Sciences and the Association of the
British Pharmaceutical Industry. Convenors Sir Alasdair Breckenridge and Virgina Acha. 2015.
https://acmedsci.ac.uk/file-download/38667-573d8796ceb99.pdf
6. Pirmohamed M, Rang H, Webb DJ. Clinical pharmacology: a dynamic medical specialty essential for
UK healthcare. A Report from the BPS, 2015.
https://www.bps.ac.uk/BPSMemberPortal/media/BPSWebsite/Clinical-Pharmacology-A-dynamicmedical-
speciality-essential-for-UK-Healthcare.pdf
7. Bruce I, Close D, Hughes A, Pirmohamed M, Savill J, Webb D. Ensuring UK leadership in
experimental medicine. A Joint Report from the ABPI and BPS, 2015.
https://www.bps.ac.uk/BPSMemberPortal/media/BPSWebsite/Assets/Ensuring-UK-leadership-inexperimental-
medicine-Aug-2015.pdf?ext=.pdf
8. Rawlins M et al. A New Pathway for the Regulation and Governance of Health Research. A Report
from the Academy of Medical Sciences. Jan 2011. ISBN No: 978-1-903401-31-6.
9. Lechler R, Anwar Q, Aronson J, Bramble M, Hays Hughes A, R, Martin J, Maskrey N, Maxwell S, Paice
E, Petty-Saphon K, Webb D, Outcomes of the Medical Schools Council Safe Prescribing Working
Group chaired by Professor Robert Lechler. November 2007.
10. Webb DJ, Wilkins MR. Safety Assessment During Pre-Marketing Clinical Trials. In Safer Medicines: A
Report from the Academy of Medical Sciences. November 2005. ISBN No: 1-903401-10-0.
11. Scottish Intercollegiate Guidelines Network (SIGN). Hypertension in Older People: A National Clinical
Guideline, Number 49, January 2001. pp. 1-49. ISBN 1-899893-42-3.
12. The Prescribing of Costly Medicines. Report of a Working Party of the Royal College of Physicians of
London, April 2000, pp. 1-74. ISBN: 1-86016-126-X
13. Clinical Pharmacology and Therapeutics in a Changing World. Report of a Working Party of the Royal
College of Physicians of London, 1999, pp. 1-76. ISBN: 1-86016-089-1

Selected Letters (from >50)
1. Baker E, Coleman J, Webb D. Challenge of multimorbidity: amplifying the impact of clinical
pharmacology and therapeutics. BMJ 2020;368:m717.
2. Webb D, Pirmohamed M. The NHS and cost-effective medicines. The Times. p. 28, Saturday, 21st
January 2017.
3. Webb DJ. Paterson KR. The importance of expertise. Sunday Herald. p. 28-29, Sun, 6th April 2014.
4. Webb DJ. Drug development critical in ongoing medical challenges [Article]. Scotsman, p. 41,
Tuesday, 21st July 2009.
5. Webb DJ. Prescribing: rising to the challenge. Scotsman, Friday, 6th February, 2009.
14
6. Griffin GE et al. UK research on verge of extinction. The Times, Wed, 14th January, 2009.
7. Aronson JK, Barnett DB, Breckenridge AM, Ferner RE, Ferro A, Jackson P, Maxwell SR, McInnes GT,
Rawlins MD, Ritter JM, Routledge P, Walley TJ, Webb DJ, Woods KL. The UK’s NHS and pharma: need
for more clinical pharmacologists. Lancet 2009;373:1251-2.
8. Griffin GE et al. UK research on verge of extinction. The Times, Wed, 14th January, 2009.
9. Aronson JK, Barnett DB, Ferner RE, Ferro A, Henderson G, Maxwell SR, McInnes GT, Rawlins MD,
Webb DJ. BMJ 2006;333:756.
download complete list of publications

[/wm_item][/wm_tabs][/vc_column][/vc_row]